[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538249":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":50,"centralContacts":54,"locations":63,"responsibleParty":243,"collaborators":245,"id":272,"slug":273,"hasResults":274,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":29,"eligibilityCriteria":278,"healthyVolunteers":274,"sex":279,"minAge":280,"maxAge":281,"enrollmentInfo":282,"targetDuration":29,"studyType":285,"phases":286,"briefSummary":289,"conditions":290,"keywords":29,"overallStatus":66,"whyStopped":29,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":304},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Camrelizumab combined neoadjuvant chemotherapy plus radical surgery","EXPERIMENTAL","Patients receive 1 cycle of cisplatin and nab paclitaxel combined neoadjuvant chemotherapy and subsequent 2 cycles of camrelizumab combined neoadjuvant chemotherapy. Based on the tumor size as indicated by MRI, patients who achieve complete response or partial response (CR\u002FPR，RECIST v1.1) will undergo open radical hysterectomy and pelvic lymph node dissection. Patients who show stable disease or progression (SD\u002FPD，v1.1) will proceed directly to concurrent chemoradiotherapy (CCRT).",[13,14,15,16],"Drug: Camrelizumab","Drug: Cisplatin","Drug: Nab paclitaxel","Procedure: Radical surgery",{"label":18,"type":19,"description":20,"interventionNames":21},"Concurrent Chemoradiotherapy (CCRT)","ACTIVE_COMPARATOR","Pelvic EBRT + concurrent platinum-containing chemotherapy + brachytherapy",[22,14],"Radiation: external beam radiation therapy (EBRT) + brachytherapy",[24,30,34,38,42,47],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Camrelizumab","Camrelizumab is administered at 200mg, q3w (second and third cycles) before radical surgery",[9],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Cisplatin","Cisplatin：75-80mg\u002Fm2, D1-D2，q3w (3 cycles)，intravenous infusion, administered at a rate of 1mg\u002Fmin.",[9],{"type":25,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"Nab paclitaxel","Nab paclitaxel: 260 mg\u002Fm2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.",[9],{"type":39,"name":40,"description":40,"armGroupLabels":41,"otherNames":29},"PROCEDURE","Radical surgery",[9],{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":29},"RADIATION","external beam radiation therapy (EBRT) + brachytherapy","Radiation therapy per standard of care",[18],{"type":25,"name":31,"description":48,"armGroupLabels":49,"otherNames":29},"Chemotherapy administered concurrent with radiation therapy，cisplatin 40 mg\u002Fm2 IV once per week (QW) for 5 weeks",[18],[51],{"name":52,"affiliation":5,"role":53},"Ding Ma","STUDY_CHAIR",[55,60],{"name":56,"role":57,"phone":58,"phoneExt":29,"email":59},"Kezhen Li","CONTACT","086-027-8362","tjkeke@126.com",{"name":61,"role":57,"phone":58,"phoneExt":29,"email":62},"Jing Chen","chenjing3223@126.com",[64,85,100,116,130,144,160,175,189,203,218,233],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"Anhui Provincial Cancer Hospital","RECRUITING","Hefei","Anhui","230000","China","CN",{"type":73,"coordinates":74},"Point",[75,76],117.28083,31.86389,{"lat":76,"lon":75},[79,82],{"name":80,"role":57,"phone":29,"phoneExt":29,"email":81},"Bairong Xia, PhD","xiabairong@ustc.edu.cn",{"name":83,"role":84,"phone":29,"phoneExt":29,"email":29},"Bairong Bairong, PhD","PRINCIPAL_INVESTIGATOR",{"facility":86,"status":66,"city":87,"state":88,"zip":29,"country":70,"countryCode":71,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Beiing Friendship Hospital, Capital Medical University","Beijing","Beijing Municipality",{"type":73,"coordinates":90},[91,92],116.39723,39.9075,{"lat":92,"lon":91},[95,98],{"name":96,"role":57,"phone":29,"phoneExt":29,"email":97},"Zhiqi Wang, PhD","wangzqnet@sina.com",{"name":99,"role":84,"phone":29,"phoneExt":29,"email":29},"Zhiqi Zhiqi, PhD",{"facility":101,"status":66,"city":102,"state":103,"zip":104,"country":70,"countryCode":71,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"The First Affiliated Hospital (Southwest Hospital), Army Medical University (Third Military Medical University)","Chongqing","Chongqing Municipality","400038",{"type":73,"coordinates":106},[107,108],106.55771,29.56026,{"lat":108,"lon":107},[111,114],{"name":112,"role":57,"phone":29,"phoneExt":29,"email":113},"Yanzhou Wang, PhD","w.y.z@foxmail.com",{"name":115,"role":84,"phone":29,"phoneExt":29,"email":29},"Yanzhou Yanzhou, PhD",{"facility":117,"status":66,"city":118,"state":119,"zip":120,"country":70,"countryCode":71,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Gansu Provincial Maternity and Child-care Hospital","Lanzhou","Gansu","730050",{"type":73,"coordinates":122},[123,124],103.83987,36.05701,{"lat":124,"lon":123},[127,129],{"name":128,"role":57,"phone":29,"phoneExt":29,"email":29},"Yun Dang, PhD",{"name":128,"role":84,"phone":29,"phoneExt":29,"email":29},{"facility":131,"status":66,"city":132,"state":133,"zip":134,"country":70,"countryCode":71,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"The Affiliated Tumor Hospital of Guangxi Medical University","Nanning","Guangxi","530021",{"type":73,"coordinates":136},[137,138],108.31667,22.81667,{"lat":138,"lon":137},[141,143],{"name":142,"role":57,"phone":29,"phoneExt":29,"email":29},"Ying Long, PhD",{"name":142,"role":84,"phone":29,"phoneExt":29,"email":29},{"facility":145,"status":66,"city":146,"state":147,"zip":148,"country":70,"countryCode":71,"cosmosGeoPoint":149,"geoPoint":153,"contacts":154},"Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology","Wuhan","Hubei","430030",{"type":73,"coordinates":150},[151,152],114.26667,30.58333,{"lat":152,"lon":151},[155,156,157,158],{"name":56,"role":57,"phone":58,"phoneExt":29,"email":59},{"name":61,"role":57,"phone":58,"phoneExt":29,"email":62},{"name":56,"role":84,"phone":29,"phoneExt":29,"email":29},{"name":159,"role":84,"phone":29,"phoneExt":29,"email":29},"Gang Chen",{"facility":161,"status":66,"city":162,"state":163,"zip":164,"country":70,"countryCode":71,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"Xiangya Hospital, Central South University","Changsha","Hunan","410008",{"type":73,"coordinates":166},[167,168],112.97087,28.19874,{"lat":168,"lon":167},[171,174],{"name":172,"role":57,"phone":29,"phoneExt":29,"email":173},"Yu Zhang, PhD","xyzhangyu@csu.edu.cn",{"name":172,"role":84,"phone":29,"phoneExt":29,"email":29},{"facility":176,"status":66,"city":177,"state":178,"zip":29,"country":70,"countryCode":71,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"Shengjing Hospital of China Medical University","Shenyang","Liaoning",{"type":73,"coordinates":180},[181,182],123.43278,41.79222,{"lat":182,"lon":181},[185,188],{"name":186,"role":57,"phone":29,"phoneExt":29,"email":187},"Tingting Gong, PhD","gongtt@sj-hospital.org",{"name":186,"role":84,"phone":29,"phoneExt":29,"email":29},{"facility":190,"status":66,"city":191,"state":192,"zip":193,"country":70,"countryCode":71,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"Second People's Hospital of Sichuan (Sichuan Cancer Hospital)","Chengdu","Sichuan","610041",{"type":73,"coordinates":195},[196,197],104.06667,30.66667,{"lat":197,"lon":196},[200,202],{"name":201,"role":57,"phone":29,"phoneExt":29,"email":29},"Dengfeng Wang, PhD",{"name":201,"role":84,"phone":29,"phoneExt":29,"email":29},{"facility":204,"status":66,"city":205,"state":206,"zip":29,"country":70,"countryCode":71,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"Tianjin Medical University General Hospital","Tianjin","Tianjin Municipality",{"type":73,"coordinates":208},[209,210],117.17667,39.14222,{"lat":210,"lon":209},[213,216],{"name":214,"role":57,"phone":29,"phoneExt":29,"email":215},"Yingmei Wang, PhD","wangyingmei@tmu.edu.cn",{"name":217,"role":84,"phone":29,"phoneExt":29,"email":29},"Yingmei Yingmei, PhD",{"facility":219,"status":66,"city":220,"state":221,"zip":222,"country":70,"countryCode":71,"cosmosGeoPoint":223,"geoPoint":227,"contacts":228},"Women's Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang","310022",{"type":73,"coordinates":224},[225,226],120.16142,30.29365,{"lat":226,"lon":225},[229,232],{"name":230,"role":57,"phone":29,"phoneExt":29,"email":231},"Yuanming Shen, PhD","5312010@zju.edu.cn",{"name":230,"role":84,"phone":29,"phoneExt":29,"email":29},{"facility":234,"status":66,"city":220,"state":221,"zip":222,"country":70,"countryCode":71,"cosmosGeoPoint":235,"geoPoint":237,"contacts":238},"Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences",{"type":73,"coordinates":236},[225,226],{"lat":226,"lon":225},[239,242],{"name":240,"role":57,"phone":29,"phoneExt":29,"email":241},"Yingli Zhang, PhD","zhangyl@zjcc.org.cn",{"name":240,"role":84,"phone":29,"phoneExt":29,"email":29},{"type":84,"investigatorFullName":56,"investigatorTitle":244,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"Prof",[246,248,250,251,253,255,257,258,260,262,264,266,268,270],{"name":247,"class":6},"Southwest Hospital, China",{"name":249,"class":6},"Women's Hospital School Of Medicine Zhejiang University",{"name":65,"class":6},{"name":252,"class":6},"Sichuan Cancer Hospital and Research Institute",{"name":254,"class":6},"Qilu Hospital of Shandong University",{"name":256,"class":6},"Beijing Friendship Hospital",{"name":204,"class":6},{"name":259,"class":6},"West China Second University Hospital",{"name":261,"class":6},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"name":263,"class":6},"Xiangya Hospital of Central South University",{"name":265,"class":6},"Gansu Provincial Maternal and Child Health Care Hospital",{"name":267,"class":6},"Zhejiang Cancer Hospital",{"name":269,"class":6},"Shengjing Hospital",{"name":271,"class":6},"Cancer Hospital of Guangxi Medical University","100538249","phase-2-neoadjuvant-chemoimmunotherapy-versus-concurrent-chemoradiotherapy-for-lacc-100538249",false,"NCT06288373","Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC","Neoadjuvant Chemoimmunotherapy Combined With Surgery Versus Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: a Multicenter Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Locally advanced (2018 FIGO staged IB3, IIA2 and IIB（tumor size\\> 4cm) ) cervical cancer，staging determined by two physicians of associate seniority or higher after gynecologic examination and imaging evaluation);\n2. At least one measurable lesion at baseline according to RECIST 1.1 criteria, with lesion size based primarily on magnetic resonance imaging;\n3. Pathologically confirmed diagnosis of cervical cancer, including cervical squamous cell carcinoma, adenocarcinoma (common type), and adenosquamous carcinoma;\n4. Positive PD-L1 expression, Combined Positive Score (CPS) ≥1;\n5. Patient age ≥18 years and ≤70 years;\n6. ECOG score ≤1;\n7. Laboratory tests: WBC (white blood cell count) ≥ 3.5×109\u002FL, NEU (neutrophil count) ≥ 1.5×109\u002FL, PLT (platelet count) ≥ 100×109\u002FL, total bilirubin ≤ 1.5 times the upper limit of normal, ALT (alanine aminotransferase) and AST (aspartate aminotransferase) ≤ 1.5 times the upper limit of normal, serum creatinine (BUN) ≤ 1.5 times the upper limit of normal or creatinine clearance ≥ 50 mL\u002Fmin (calculated using the Cockcroft-Gault formula, the Chronic Kidney Disease Epidemiology Collaboration equation, or the Modification of Diet in Renal Disease equation);\n8. Be willing to follow up and good compliance;\n9. Be willing to sign the informed consent, including compliance with the requirements and restrictions listed in the informed consent and program；\n10. Agree to use effective contraception measures during the trial period and for 5 months after the last dose of pembrolizumab or 6 months after chemotherapy (whichever is longer).\n\nExclusion Criteria:\n\n1. Any active autoimmune disease or history of autoimmune disease requiring systemic treatment, including but not limited to autoimmune hepatitis, interstitial pneumonitis, uveitis, enterocolitis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, thyroid dysfunction, asthma requiring bronchodilator intervention;\n2. Prior treatment with immune checkpoint inhibitors, including but not limited to other anti-PD-1 and anti-PD-L1 antibodies; known hypersensitivity to any component of the study medication or other monoclonal antibodies;\n3. Has a history of human immunodeficiency virus (HIV) infection, active hepatitis B (HBV-DNA ≥ 2000 IU\u002FmL or 104 copies\u002FmL), and hepatitis C (HCV antibody positive, and HCV-RNA above the lower limit of detection of the assay);\n4. Receipt of immunosuppressive medications or systemic corticosteroid therapy for immunosuppression (\\>10 mg\u002Fday prednisone or equivalent) within 2 weeks prior to study dosing;\n5. Diagnosed with another primary malignancy within 5 years prior to the first use of the investigational drug;\n6. Received other investigational drugs\u002Ftreatments or participated in another clinical trial within 4 weeks prior to randomization. Participation in observational and non-interventional clinical trials is allowed;\n7. Pregnant or breastfeeding female patients;\n8. Uncontrolled co-morbidities, including but not limited to New York Heart Association (NYHA) class 2 or higher, severe\u002Funstable angina pectoris, myocardial infarction within ≤ 6 months prior to study drug administration, severe arrhythmias requiring medication or intervention; difficult-to-control hypertension; cerebral vascular accidents or brain disorders within ≤ 6 months prior to study drug administration, or individuals with adjudicated abnormal behavioral skills; hematologic disorders: coagulation abnormalities (INR \\>2. 0, PT\\>16s), bleeding tendency, or undergoing thrombolytic or anticoagulant therapy; abnormalities in hepatic or renal development or a history of surgery; and development of an active infection requiring systemic anti-infective therapy within 14 days prior to the first dose of study drug;\n9. Treatment with a live or attenuated vaccine administered within 4 weeks prior to the first dose of study drug; inactivated seasonal influenza virus vaccine is permitted;\n10. Patients with a prior allogeneic bone marrow or solid organ transplant;\n11. Drug and\u002For alcohol abuse;\n12. Patients who, in the opinion of the investigator, are unlikely to comply with the procedures, restrictions, and requirements of the study may not be enrolled in the study.","FEMALE","18 Years","70 Years",{"count":283,"type":284},440,"ESTIMATED","INTERVENTIONAL",[287,288],"PHASE2","PHASE3","It is a prospective, open-label, randomized, controlled phase II\u002FIII clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB（tumors \\>4 cm in diameter）will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group.",[291,292,293,294],"Cervical Cancer","Locally Advanced Cervical Cancer","Concurrent Chemoradiotherapy","Neoadjuvant Chemoimmunotherapy","2024-10-26",{"date":297,"type":298},"2024-10-30","ACTUAL",{"date":300,"type":298},"2024-04-22",{"date":302,"type":284},"2031-03-01",{"name":5,"class":6},12]